Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 24;3(1):vdab085. doi: 10.1093/noajnl/vdab085

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — In vivo activity of palbociclib and hypofractionated RT against IOMM-Lee meningiomas. BLI (A) and survival (B) results for IOMM-Lee model. RT administered days 3–7 post tumor cell injection: 2 Gy/day × 5 days. Palbociclib administered days 3–10 post tumor cell injection 150 mg/kg/day. For (A), *P < 0.001 for RT + palbociclib vs. any other treatment group. For (B), *P < 0.05 for RT + palbociclib vs. control, and for RT + palbociclib vs. palbociclib only. N = 7 for control, 10 for palbociclib, 8 for RT, 9 for RT + palbociclib.